Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition of R848 or medicine composition of combination of R848 and sorafenib for treating cancer and application

A combination therapy, R848 technology, applied in the field of pharmaceutical compositions for the treatment of cancer, can solve the problems of easy drug resistance, low therapeutic efficacy, and many side effects

Pending Publication Date: 2020-09-15
TIANJIN TUMOR HOSPITAL
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] In order to provide a more effective means for the treatment of cancers such as liver cancer, in particular, in order to solve the problems of low therapeutic efficacy, many side effects, and easy drug resistance caused by sorafenib monotherapy in the treatment of cancers such as liver cancer, the invention of the present invention People have conducted a lot of research, and unexpectedly found that the use of R848 alone or in combination with R848 and Sorafenib has achieved good curative effect in the mouse liver cancer xenograft model, and the combined effect is significantly better than Sorafenib It can be used alone with R848, and there is no obvious side effect within a certain dose range, which provides a new possibility for the clinical treatment of liver cancer patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition of R848 or medicine composition of combination of R848 and sorafenib for treating cancer and application
  • Medicine composition of R848 or medicine composition of combination of R848 and sorafenib for treating cancer and application
  • Medicine composition of R848 or medicine composition of combination of R848 and sorafenib for treating cancer and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1. Establishment of mouse tumor model

[0058] Hep1-6 cells (liver cancer cell line preserved in the applicant's cell room) were stored in DMEM supplemented with 10% fetal bovine serum at 37°C and 5% CO 2 cultivated under conditions. Hep1-6 cells were subcutaneously inoculated into C57 mice (purchased from Beijing Weitong Lihua Company, male mice, 4-5 weeks old, weighing about 20 g), and each mouse was inoculated with 1×10 6 cells (day 0). Cells were allowed to grow into tumors, and mice were then randomly divided into four groups (n=10): 1) control group, 2) sorafenib group, 3) R848 group, and 4) sorafenib+R848 combination Each group was given the corresponding drug or vehicle (from the 10th day to the 31st day).

Embodiment 2

[0059] Example 2. Dosing regimen and parameter measurement

[0060] Sorafenib (Bayer, GER) was dissolved in a 1:1 formulation of castor oil and ethanol, diluted with saline (final working concentration was 4 mg / ml, and the intragastric volume was about 50 μl / mouse).

[0061] R848 (Selleck, USA) was dissolved in ethanol and diluted with saline (final working concentration was 0.2 mg / ml, injection volume was 100 μl / mouse).

[0062] The mice in the Sorafenib group were given Sorafenib alone, administered orally, at a dose of 10 mg / kg mouse body weight, once a day, 5 times a week, for a total of 21 days.

[0063] Mice in the R848 group were given R848 alone, intratumoral injection at a dose of 20 μg / mouse, twice a week for 21 days in total.

[0064] The mice in the combination drug group were given Sorafenib and R848 as above, the administration dose was the same as above, and the administration frequency was the same as that of each single drug group, that is, Sorafenib was once...

Embodiment 3

[0068] Example 3. Results Evaluation

[0069] 3.1 Tumor volume and tumor weight in mice

[0070] At the end of the 21-day treatment, mice in each group remained alive. Such as Figure 1A to Figure 1C As shown, R848 alone showed a significant tumor reduction effect after the end of treatment. Since the dose of Sorafenib (about 200 μg / mouse in a single dose) is much higher than that of R848, R848 appears to be more potent than Sorafenib. In addition, compared with single administration of Sorafenib (10mg / kg) or R848 (20μg / mouse), the combination regimen significantly inhibited the tumor volume ( Figure 1A and Figure 1C ) and tumor weight ( Figure 1B ).

[0071] In particular, if Figure 1B As shown in Table 1, compared with the vehicle control, Sorafenib alone reduced the tumor weight to about 76%, but it has not yet reached a statistically significant level; R848 alone reduced the tumor weight to about 36%, with statistical However, the combined drug group reduced the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a medicine composition of R848 or a medicine composition of a combination of the R848 and sorafenib for treating cancer and an application. Specifically, the invention relates to an application of R848 or a combination of the R848 and sorafenib in preparation of a medicament for treating cancer, and a pharmaceutical composition which is used for treating cancer and comprisesthe R848 and / or sorafenib. The cancers include, but are not limited to, kidney cancer, liver cancer, thyroid cancer or fibroma, preferably hepatocellular carcinoma (HCC), in particular advanced hepatocellular carcinoma, non-resectible hepatocellular carcinoma, or distally metastatic primary hepatocellular carcinoma.

Description

technical field [0001] The present invention relates to the field of cancer treatment, in particular, the present invention relates to the pharmaceutical composition, method and use of R848 or R848 combined with sorafenib to treat cancer. Background technique [0002] Hepatocellular carcinoma (hepatocellular carcinoma, HCC) is the third malignant tumor with the highest mortality rate in the world. Chinese patients account for more than 50% of the world's liver cancer patients, and its morbidity and mortality are high, and the five-year survival rate is less than 20%. The status of its treatment is not optimistic. Most patients with liver cancer have entered the middle and late stages when they are diagnosed, and have lost the best chance for surgery. [0003] Sorafenib, also known as Nexavar, with a CAS number of 284461-73-0, is a first-line targeted therapy drug for advanced liver cancer in recent years. It has been on the market in China for nearly ten years, and it has b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/44A61K31/4188A61K31/475A61K31/704A61K31/407A61K33/243A61K31/337A61P35/00A61P35/04
CPCA61K31/44A61K31/4188A61K31/475A61K31/704A61K31/407A61K33/24A61K31/337A61P35/00A61P35/04A61K2300/00
Inventor 张宁郭华贺钰超
Owner TIANJIN TUMOR HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com